My watch list  

239 Current news about the topic monoclonal antibodies


You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
Vaccination success without B cells

Communication between immune cells determines response to vaccination


Immunosuppressed patients often cannot build up good protection after a vaccination because the necessary cells of the immune system function less well or are not present at all. This has been studied especially in the drug therapy of rheumatoid arthritis. Scientists from TWINCORE and the ...


image description
Anti-cancer drug’s mode of operation deciphered

How the membrane protein CD20 keeps the immune system’s antibody-producing cells in check


Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy ...


image description
Two anti-inflammatory compounds shown to be capable of accelerating recovery from COVID-19

Monoclonal antibody and experimental drug given to patients promoted rapid improvement of respiratory function in patients in severe condition


Two independent clinical studies – one by researchers at the Center for Cell-Based Therapy (CTC) in Ribeirão Preto, state of São Paulo (Brazil), on the monoclonal antibody eculizumab, and the other by scientists at the University of Pennsylvania in Philadelphia (USA) on an experimental drug ...


image description
Evotec to produce monoclonal antibody products against COVID-19 for the Department of Defense

Contract valued up to $ 18.2 m


Evotec SE announced that the U.S. Department of Defense (“DOD”) awarded its Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $ 18.2 m to develop and manufacture monoclonal antibodies (“mAbs”) for treatment and/or prevention of COVID-19. The goal of this programme is ...


image description
GSK and CureVac announce strategic mRNA technology collaboration

Companies to collaborate on mRNA vaccine and monoclonal antibody research programmes in infectious diseases


GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements ...


Lasker Award 2019 for the invention of Herceptin


Herceptin was the first monoclonal antibody that blocks a cancer causing protein. For the invention of Herceptin and the development of a life-saving therapy for women with breast cancer, three researchers are now receiving the Lasker~DeBakey Clinical Medical Research Award: Axel Ullrich, ...


image description
€ 1 Million Research Grant Awarded for the First Time

Merck awarded a grant known as the Future Insight Prize for the first time


Merck awarded a grant known as the Future Insight Prize for the first time. Pardis Sabeti, Harvard University and the Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA, and James Crowe, Vanderbilt University Medical Center, Nashville, Tennessee, USA, were recognized for their ...


image description
First use of vasoprotective antibody in cardiogenic shock


Scientists at the German Centre for Cardiovascular Research (DZHK) have started a study to find out whether a monoclonal antibody restoring vascular integrity is safe and has positive effects on organ functions of patients with cardiogenic shock. The multicenter trial is sponsored by the ...


Swiss-French biotech start-up launches

ALENTIS Therapeutics raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer


ALENTIS Therapeutics, a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced the completion of a Series A financing of CHF 12.5million (Euro 11.1m; USD 12.5m). The Swiss venture capital firms BioMedPartners and BB Pureos Bioventures co-led the ...


MorphoSys received a milestone payment from Janssen

Janssen has Expanded Clinical Development of Guselkumab into Familial Adenomatous Polyposis


MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has further expanded the clinical development of guselkumab (Tremfya(R)) into familial adenomatous polyposis (FAP), a disease of the gastrointestinal tract. Janssen has initiated a phase 1b proof-of-concept clinical ...


Page 1 From 24
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE